Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 2015;36(6):418–24.
Article
PubMed
Google Scholar
Sheehan WJ, Phipatanakul W. Difficult-to-control asthma: epidemiology and its link with environmental factors. Curr Opin Allergy Clin Immunol. 2015;15(5):397–401.
Article
CAS
PubMed
PubMed Central
Google Scholar
Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014;9(4):187–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56(4):279–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S7–10.
Article
PubMed
Google Scholar
Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12.
Article
PubMed
PubMed Central
Google Scholar
Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017;124:36–43.
Article
PubMed
Google Scholar
Cisneros Serrano C, Melero Moreno C, Almonacid Sanchez C, Perpina Tordera M, Picado Valles C, Martinez Moragon E, et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol. 2015;51(5):235–46.
Article
PubMed
Google Scholar
Global Initiative of Asthma. 2018 GINA Report, global strategy for asthma management and prevention. [cited 2018 24 Julio]; https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed 24 July 2018.
Guía Española para el Manejo del Asma (GEMA 4.2). 2017. http://www.gemasma.com. Accessed 15 May 2017.
Suzuki C, Silva LDN, Kumar P, Pathak P, Ong SH. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–9.
Article
PubMed
Google Scholar
van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342–8.
Article
PubMed
Google Scholar
Levy AN, Ruiz GAAJ, Garcia-Agua Soler N, Sanjuan MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–10.
Article
PubMed
Google Scholar
Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–78.
Article
PubMed
Google Scholar
Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008;63(6):670–84.
Article
CAS
PubMed
Google Scholar
Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1–342.
Article
CAS
PubMed
PubMed Central
Google Scholar
Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value in health regional issues. 2013;2(1):29–36.
Article
PubMed
Google Scholar
Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765–76.
Article
CAS
PubMed
Google Scholar
Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111(1):87–90.
Article
CAS
PubMed
Google Scholar
Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma. Cochrane Database Syst Rev. 2003. https://doi.org/10.1002/14651858.CD003559.
Article
PubMed
Google Scholar
Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost effectiveness of pharmacological treatments for asthma: a systematic review. Pharmacoeconomics. 2018;36(10):1165–200.
Article
PubMed
Google Scholar
McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics 2018;36:957. https://doi.org/10.1007/s40273-018-0658-x.
Article
PubMed
Google Scholar
Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124(4):719e1–723e1.
Article
Google Scholar
Gisbert R, Brosa M. eSalud Healthcare cost database: Oblikue Consulting, S.L.. 2012. http://www.oblikue.com/bddcostes. Accessed 9 Sept 2015.
BotPlus: Healthcare Knowdlege database. 2016. https://botplusweb.portalfarma.com/. Accessed 18 May 2016.
Instituto Nacional de estadística (INE). 2016. http://www.ine.es/. Accessed 18 May 2016.
Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103(11):1725–31.
Article
CAS
PubMed
Google Scholar
Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104(10):1410–6.
Article
CAS
PubMed
Google Scholar
Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012;25(1):77–82.
Article
CAS
PubMed
Google Scholar
Vennera MDC, Perez De Llano L, Bardagi S, Ausin P, Sanjuas C, Gonzalez H, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry–some new approaches. J Asthma. 2012;49(4):416–22.
Article
CAS
Google Scholar
Schumann C, Kropf C, Wibmer T, Rudiger S, Stoiber KM, Thielen A, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012;6(4):215–27.
Article
CAS
PubMed
Google Scholar
Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102(1):71–6.
Article
PubMed
Google Scholar
Lopez Tiro JJ, Contreras EA, del Pozo ME, Gomez Vera J, Larenas Linnemann D. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol (Madr). 2015;43(2):120–6.
Article
Google Scholar
Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104(9):1381–5.
Article
CAS
PubMed
Google Scholar
Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012;49(1):78–82.
Article
CAS
PubMed
Google Scholar
Subramaniam A, Al-Alawi M, Hamad S, O’Callaghan J, Lane SJ. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland. QJM. 2013;106(7):631–4.
Article
CAS
PubMed
Google Scholar
Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci. 2011;180(3):637–41.
Article
CAS
PubMed
Google Scholar
Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62(2):149–53.
Article
CAS
PubMed
Google Scholar
Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49(8):843–8.
Article
CAS
Google Scholar
Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610.
Article
CAS
PubMed
Google Scholar
Domingo C, Pomares X, Navarro A, Rudi N, Sogo A, Davila I, et al. Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens: a pilot study. Int J Mol Sci. 2017;18(3):521.
Article
CAS
PubMed Central
Google Scholar